308 related articles for article (PubMed ID: 23620484)
1. The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.
Tsakalozou E; Adane ED; Kuo KL; Daily A; Moscow JA; Leggas M
Drug Metab Dispos; 2013 Jul; 41(7):1404-13. PubMed ID: 23620484
[TBL] [Abstract][Full Text] [Related]
2. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
3. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
5. Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.
Lee HH; Leake BF; Teft W; Tirona RG; Kim RB; Ho RH
Mol Cancer Ther; 2015 Apr; 14(4):994-1003. PubMed ID: 25695959
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
7. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
Kindla J; Müller F; Mieth M; Fromm MF; König J
Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
Ishiguro N; Maeda K; Saito A; Kishimoto W; Matsushima S; Ebner T; Roth W; Igarashi T; Sugiyama Y
Drug Metab Dispos; 2008 Apr; 36(4):796-805. PubMed ID: 18180273
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.
Jiang R; Dong J; Li X; Du F; Jia W; Xu F; Wang F; Yang J; Niu W; Li C
Br J Pharmacol; 2015 Feb; 172(4):1059-73. PubMed ID: 25297453
[TBL] [Abstract][Full Text] [Related]
12. Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport.
Mahagita C; Grassl SM; Piyachaturawat P; Ballatori N
Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G271-8. PubMed ID: 17412826
[TBL] [Abstract][Full Text] [Related]
13. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Oostendorp RL; van de Steeg E; van der Kruijssen CM; Beijnen JH; Kenworthy KE; Schinkel AH; Schellens JH
Drug Metab Dispos; 2009 Apr; 37(4):917-23. PubMed ID: 19139163
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.
Lee HH; Leake BF; Kim RB; Ho RH
Mol Pharmacol; 2017 Jan; 91(1):14-24. PubMed ID: 27777271
[TBL] [Abstract][Full Text] [Related]
15. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.
Sato T; Yamaguchi H; Kogawa T; Abe T; Mano N
J Pharm Pharm Sci; 2014; 17(4):475-84. PubMed ID: 25579430
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier transporters and response to CNS-active drugs.
Urquhart BL; Kim RB
Eur J Clin Pharmacol; 2009 Nov; 65(11):1063-70. PubMed ID: 19727692
[TBL] [Abstract][Full Text] [Related]
17. Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake.
Hove VN; Anderson K; Hayden ER; Pasquariello KZ; Gibson AA; Shen S; Qu J; Jin Y; Miecznikowski JC; Hu S; Sprowl JA
Mol Pharmacol; 2022 Jun; 101(6):381-389. PubMed ID: 35383108
[TBL] [Abstract][Full Text] [Related]
18. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
19. OATP1B3-1B7, a novel organic anion transporting polypeptide, is modulated by FXR ligands and transports bile acids.
Malagnino V; Hussner J; Issa A; Midzic A; Meyer Zu Schwabedissen HE
Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G751-G762. PubMed ID: 31509437
[TBL] [Abstract][Full Text] [Related]
20. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
